Beleaguered price-hiking drug CEO says he wasn't defending Shkreli, he was condemning FDA

Nirmal Mulye, founder of Nostrum Pharmaceuticals, argues the generic drug business has become so bogged down in inefficiencies at the Food and Drug Administration, his business lost money in eight of the past 11 years.


Related Articles